Cystic Fibrosis Breakthrough Transforms Lives: A Personal Journey

Nicole Adams, a 34-year-old from Newtownabbey, Northern Ireland, has experienced a remarkable transformation in her life thanks to groundbreaking research conducted at Queen’s University Belfast. Diagnosed with cystic fibrosis (CF) as a child, Adams faced a challenging future marked by frequent hospital visits and a rigorous treatment regimen. However, the introduction of the revolutionary drug Kaftrio has significantly improved her health and life expectancy, allowing her to embrace a future she once thought unattainable.

Cystic fibrosis is a genetic disorder that leads to the production of thick mucus, affecting the lungs and digestive system. Traditionally, treatments focused on managing symptoms rather than addressing the underlying causes. The discovery of the CFTR gene in 1989 marked a pivotal moment in CF research, paving the way for therapies that target the root of the disease. Queen’s University has been at the forefront of this research for over 15 years, contributing to the development of Kaftrio, which has been hailed as a game-changer for patients.

Adams began taking Kaftrio after a severe lung infection in 2019 left her hospitalized. Under the guidance of her doctor, Prof. Damian Downey, who advocated for her access to the drug prior to its regulatory approval in the UK, Adams experienced a rapid improvement in her health. Within 48 hours of starting the treatment, she was able to leave the hospital and regain her strength. Adams now describes her life as one of living, not merely surviving, and she has even realized her dream of becoming a mother.

The clinical trials for Kaftrio, which demonstrated its efficacy in addressing the underlying causes of cystic fibrosis for approximately 90% of patients, were supported by a collaborative network of cystic fibrosis centers across Europe. Prof. Downey emphasized the importance of the active CF community in facilitating these trials, highlighting how coordinated efforts among patients, clinicians, and researchers can accelerate drug development. As a result, Kaftrio received regulatory approval in the UK in 2020, marking a significant milestone in CF treatment.